Table 1 Patient characteristics, prior treatments and laboratory values at baseline before start of docetaxel chemotherapy for 67 patients.
All n = 67 | Group 1 mCNPC n = 7 | Group 2 mCRPC n = 26 | Group 3 mCRPC-ART n = 34 | p value | |
|---|---|---|---|---|---|
Age, median | 69 | 69 | 68.5 | 69 | |
ECOG, no. (%) | |||||
0 | 22 (32.8) | 3 (42.9) | 12 (46.2) | 7 (20.6) | |
1 | 31 (46.3) | 4 (57.1) | 11 (42.3) | 16 (47.1) | |
2 | 10 (14.9) | 0 | 3 (11.5) | 7 (20.6) | |
3 | 4 (6) | 0 | 0 | 4 (11.8) | 0.009 |
Gleason score 8–10, no. (%) | 36 (53.7) | 2 (28.6) | 15 (57.7) | 19 (55.9) | |
BMI | 26.2 | 24.7 | 27.8 | 25.3 | 0.025 |
Metastases | |||||
No. of organs, no. (%) | |||||
1 | 28 (41.8) | 2 (28.6) | 13 (50) | 13 (38.2) | |
2 | 24 (35.8) | 3 (42.8) | 5 (19.2) | 16 (47.1) | |
≥ 3 | 15 (22.4) | 2 (28.6) | 8 (30.8) | 5 (14.7) | |
Bone | 64 (95.5) | 7 (100) | 25 (96.2) | 32 (94.1) | |
Soft tissue | 42 (62.7) | 5 (71.4) | 14 (53.9) | 23 (67.7) | |
Lymph nodes | 34 (50.8) | 5 (71.4) | 12 (46.2) | 17 (50) | |
Lungs | 11 (16.4) | 1 (14.3) | 6 (23.1) | 4 (11.8) | |
Liver | 11 (16.4) | 0 | 5 (19.2) | 6 (17.7) | |
Brain | 2 (3) | 0 | 2 (7.7) | 0 | |
Cancer pain, no. (%) | 38 (56.7) | 6 (85.7) | 14 (53.9) | 18 (52.9) | |
Non-narcotics required, no. (%) | 26 (38.8) | 4 (57.1) | 8 (30.8) | 14 (41.2) | |
Narcotics required, no. (%) | 23 (34.3) | 2 (28.6) | 7 (26.9) | 14 (41.2) | |
Prior treatment | |||||
Local therapy | |||||
Radical prostatectomy, no. (%) | 24 (35.8) | 0 | 13 (50) | 11 (32.4) | 0.015 |
TUR-prostate, no. (%) | 13 (19.4) | 0 | 7 (26.9) | 6 (17.7) | |
Radiotherapy | |||||
RTX prostate, no. (%) | 19 (28.4) | 0 | 8 (30.8) | 11 (32.4) | |
RTX bone, no. (%) | 34 (50.8) | 3 (42.9) | 14 (53.9) | 17 (50) | |
RTX soft tissue, no. (%) | 10 (14.9) | 0 | 4 (15.4) | 6 (17.7) | |
Radiopharmaceuticals | |||||
Alpharadin, no. (%) | 3 (4.5) | 0 | 0 | 3 (8.8) | |
PSMA ligands, no. (%) | 1 (1.5) | 0 | 0 | 1 (2.9) | |
Duration of ADT in months | 17 (0–108) | 0 | 22.5 | 25 | 0.008 |
ART | |||||
Abiraterone, no. (%) | 29 (43.3) | 0 | 0 | 29 (85.3) | < 0.001 |
Enzalutamide, no. (%) | 20 (29.9) | 0 | 0 | 20 (58.8) | 0.009 |
Ketoconazole, no. (%) | 2 (3) | 0 | 1 (3.9) | 1 (2.9) | |
Estramustine, no. (%) | 5 (7.5) | 0 | 4 (15.4) | 1 (2.9) | |
Prior docetaxel, no. (%) | 18 (26.8) | 0 | 5 (19.2) | 13 (38.2) | |
Laboratory at baseline | |||||
PSA (μg/L), median (range) | 129.7 (4.26–6695) | 737.9 | 102.85 | 128.3 | 0.001 |
FT (pg/mL), median (range) | 0.315 (0.18–15.3) | 1.92 | 1.14 | 0.18 | < 0.001 |
TT (ng/mL), median (range) | 0.12 (0.05–4.86) | 2.4 | 0.19 | 0.12 | < 0.001 |
Hb (g/dL), median (range) | 11.5 (7.4–15.6) | 10.2 | 12.1 | 11.5 | 0.029 |
AP (U/L), median (range) | 151 (44–4834) | 307 | 122 | 146 | |
> ULN, no. (%) | 36 (53.7) | 7 (100) | 12 (46.2) | 17 (50) | |
> 2xULN, no. (%) | 23 (34.3) | 5 (71.4) | 7 (26.9) | 11 (32.4) | |
LDH (U/L), median (range) | 285 (158–1266) | 422 | 278 | 276.5 | |
> ULN, no. (%) | 41 (61.2) | 6 (85.7) | 16 (61.5) | 19 (55.9) | |
> 2 × ULN, no. (%) | 13 (19.4) | 1 (14.3) | 6 (23.1) | 6 (17.7) | |
NSE (μg/L), median (range) | 21 (11–56) | 22.5 | 20 | 23 | |
> ULN, no. (%) | 40 (59.7) | 5 (71.4) | 13 (50) | 22 (64.7) | |
CgA (μg/L), median (range) | 149.5 (2–664) | 177 | 90 | 189 | |
> ULN, no. (%) | 42 (62.7) | 6 (85.7) | 13 (50) | 23 (67.7) | |
CgA/NSE > ULN, no. (%) | 49 (73.1) | 7 (100) | 17 (65.4) | 26 (76.5) | |
CgA and NSE > ULN, no (%) | 31 (61.2) | 4 (57.1) | 9 (34.6) | 19 (55.9) | 0.018 |
NLR, median | 5.8 | 5.3 | 4.9 | 6.9 | |
